## 5.5.5 CONCRETE EMERGENCY-MODE WORKFLOW: MASS VACCINATION SAFETY SURVEILLANCE

### 5.5.5.1 Operational Scenario

**Scenario:** A regional vaccination campaign experiences a sudden increase in adverse-event reports across multiple hospitals and vaccination centres. Reports include common, expected post-immunization reactions, a small number of serious cardiovascular or immune-mediated events, incomplete clinical narratives, and repeated submissions concerning the same patients.

Vyom enters **Emergency Surveillance Mode (ESM)** to increase ingestion capacity, prioritize clinically significant cases, identify potential temporal-spatial clusters, and preserve regulatory reporting controls.

The workflow is designed to support safety professionals and public-health authorities. It does not autonomously establish causality, order a product recall, or replace statutory reporting procedures.

### 5.5.5.2 End-to-End Workflow

| Stage | Trigger and system action | Output and control |
|---|---|---|
| **1. Emergency activation** | An authorized operator activates ESM following a predefined surge threshold, a public-health notification, or an approved incident declaration. | Incident ID, activation timestamp, designated owner, operating parameters, and escalation contacts. |
| **2. High-throughput ingestion** | Durable queues accept approved EHR feeds, vaccination records, spontaneous reports, emergency department notes, and call-centre records. | Persisted source events, ingestion timestamps, source identifiers, and queue-health metrics. |
| **3. Clinical extraction** | OCR, document parsing, and clinical NLP extract candidate events, product names, administration dates, symptoms, outcomes, and batch identifiers where present. | Structured candidate records with source references, confidence values, and unresolved-field flags. |
| **4. Deduplication and linkage** | Deterministic identifiers and probabilistic matching identify possible duplicate reports, follow-ups, and related encounters. | Linked case candidates with match evidence; uncertain matches remain separate pending review. |
| **5. Case validation and coding** | The rules engine checks minimum case criteria and proposes version-controlled MedDRA LLTs and product mappings. | Validity status, coding candidates, completeness findings, and reviewer queue assignment. |
| **6. Priority triage** | Seriousness, clinical indicators, product-quality information, and predefined escalation rules determine routing priority. | Prioritized work queues. Urgent cases are routed for immediate human assessment according to the approved protocol. |
| **7. Temporal-spatial analysis** | The surveillance engine aggregates eligible records by product, event, exposure time, geography, institution, and batch where available. | Candidate clusters, baseline comparisons, uncertainty measures, and supporting case references. |
| **8. Signal review** | Qualified safety personnel review the alert, assess clinical plausibility, examine alternative explanations, and document a disposition. | Escalated signal, further investigation, monitored anomaly, or documented dismissal with rationale. |
| **9. Regulatory case preparation** | Approved case records are mapped to the applicable ICH E2B(R3) implementation profile and validated against schemas and business rules. | Versioned XML, validation report, unresolved errors, and release status. |
| **10. Authorized submission and reconciliation** | Authorized personnel transmit eligible reports through the applicable approved channel and monitor acknowledgements or rejections. | Submission identifiers, transmission evidence, acknowledgement status, and follow-up tasks. |
| **11. Incident monitoring and deactivation** | The incident lead reviews queue recovery, outstanding high-priority cases, cluster disposition, and backlog trends. | Signed incident review, outstanding-action register, deactivation timestamp, and post-incident report. |

### 5.5.5.3 Illustrative Event-Processing Logic

The following is a proposed operational sequence, not a validated production algorithm.

```text
ON emergency_mode_activated(incident_id):

    load approved incident configuration
    verify data-source permissions and access controls
    initialize durable queues and monitoring
    record activation event

ON safety_record_received(record):

    persist_original_record(record)
    assign_source_id_and_ingestion_timestamp(record)

    candidate = extract_clinical_information(record)
    attach_source_provenance(candidate)

    IF critical fields are uncertain:
        route_to_priority_human_review(candidate)

    match_result = detect_possible_duplicates(candidate)
    preserve_match_evidence(match_result)

    validated_case = apply_case_validity_and_quality_rules(candidate)

    IF validated_case meets escalation criteria:
        enqueue_for_qualified_safety_review(validated_case)

    IF validated_case is eligible for analysis:
        update_approved_surveillance_aggregates(validated_case)

    anomaly = evaluate_configured_signal_rules()

    IF anomaly exceeds approved screening criteria:
        create_traceable_alert(anomaly)
        notify_authorized_reviewers(anomaly)

    IF case is approved for regulatory compilation:
        generate_E2B_R3_XML(case)
        validate_schema_and_business_rules(case)
        route_to_authorized_release_workflow(case)

    record_processing_outcome_and_rule_versions()
```

The implementation must be idempotent, preserve original source records, handle late-arriving data, and support replay after service interruption. A statistical anomaly must generate an investigation workflow—not an automatic causality determination or regulatory action.

### 5.5.5.4 Illustrative Cluster-Escalation Example

Assume that several hospitals report a similar serious clinical event following administration of the same vaccine during a defined observation period. The reports contain inconsistent product names, incomplete onset dates, and possible duplicates.

Vyom should:

1. Normalize the reported product identity where sufficient evidence exists.
2. Separate confirmed exposure records from unresolved product matches.
3. identify potential duplicates without automatically merging uncertain cases.
4. Calculate observed counts and evaluate the pattern using an approved method and an appropriate baseline.
5. Display the underlying reports, missing data, exposure denominator limitations, and uncertainty.
6. Route the candidate cluster to the designated pharmacovigilance and public-health reviewers.
7. Record the review decision, requested follow-up, and any authorized escalation.
8. Continue monitoring the cluster as additional cases and corrections arrive.

**No alert threshold should be interpreted as proof that the vaccine caused the events.** Statistical screening, clinical assessment, epidemiological investigation, and regulatory decision-making remain distinct stages.

### 5.5.5.5 Emergency-Mode Service-Level Indicators

The emergency operating dashboard should report:

- Ingestion throughput and queue depth.
- Age of the oldest unprocessed record.
- Extraction and case-validation latency at p50, p95, and p99.
- Critical-field extraction accuracy on an adjudicated sample.
- Potential duplicate rate and reviewer-confirmed matching accuracy.
- Number of serious cases awaiting human assessment.
- Candidate-cluster count and time to qualified review.
- E2B(R3) schema-validation pass rate.
- Submission acknowledgements, rejections, and unresolved follow-ups.
- System availability, retry rate, and recovery status.

The sub-100-millisecond objective applies only to the specifically benchmarked deterministic processing stage. Full document extraction, clinical interpretation, signal confirmation, and regulatory submission require separate end-to-end measurements.

### 5.5.5.6 Emergency Deactivation and Post-Incident Review

Emergency mode should be deactivated only by an authorized incident owner after reviewing workload recovery, unresolved high-priority cases, active signals, and downstream reconciliation.

The post-incident review should document:

- Peak and sustained record volumes.
- Queue saturation and recovery intervals.
- Cases requiring manual correction.
- Alerts raised, investigated, and dispositioned.
- Data-source and integration failures.
- Regulatory reporting exceptions.
- Model, terminology, and rule versions used.
- Corrective and preventive actions.

The resulting report should provide an auditable account of system performance and operational decisions during the surge. It should not attribute improved clinical outcomes to the software without a suitable evaluation design and supporting evidence.